AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key products' loss of exclusivity in the 2030s, and rapidly growing therapies offsetting near-term risks. The pipeline is robust and diversified, targeting 20 new molecular entities by 2030, supporting management's ambition to nearly double revenues to $80B.

Seeking Alpha • Dec 10, 2025

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% Favorable safety profile with most (87%) adverse events being mild or moderate and no treatment-related discontinuations The safety run-in portion is complete with no apparent differences in safety or efficacy between the two dose levels; the signal-seeking expansion phase of the study is ongoing LUND, SE / ACCESS Newswire / December 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune‑modulatory antibodies for cancer immunotherapy, today announced the presentation of new data from the safety run-in portion of its ongoing trial evaluating BI-1206, an anti-FcγRIIB antibody, in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Anti-CD20 antibodies like rituximab are essential for treating NHL.

Accesswire • Dec 8, 2025

Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing

JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in global pharma. The bank says a wave of clinical readouts (and a high likelihood of success) positions AstraZeneca to benefit disproportionately as investors shift their attention away from US drug-pricing fears and back towards innovation.

Proactive Investors • Dec 8, 2025

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025. This year's ASH congress will feature the Company's largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated r.

Business Wire • Dec 4, 2025

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliv.

Business Wire • Dec 4, 2025

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Dec 3, 2025

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.

Zacks Investment Research • Dec 3, 2025

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 202.

Business Wire • Dec 2, 2025

BREAKING: Trump strikes major deal with UK on drug pricing

FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'

Fox Business • Dec 1, 2025

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 28, 2025